ArticleJTO clinical and research reports2025
Genetic Characteristics of Disease Flare After Lenvatinib Discontinuation in Patients With Thymic Carcinoma: A Brief Report.
Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.Mediastinum (Hong Kong, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lenvatinib, an orally administered multitargeted kinase inhibitor, has exhibited antitumor activity against several cancer types, including thymic carcinomas. Although "disease flare" (a rapid worsening of the tumor on the discontinuation of lenvatinib) has been reported, such cases are rare in thymic carcinoma. Understanding this phenomenon is clinically significant, as it may cause rapid deterioration requiring urgent therapeutic intervention and patient death. This retrospective study aimed to determine the frequency and characteristics of disease flares in patients with thymic carcinoma. Methods: We retrospectively reviewed the records of patients with thymic carcinoma who received lenvatinib between January 2018 and March 2024 at the National Cancer Center Hospital in Tokyo, Japan. Patients were categorized into flare and nonflare groups, with their characteristics, clinical outcomes, and genetic profiles compared. Results: Of the 52 patients, four patients (8%) experienced disease flares after lenvatinib failure. Baseline characteristics according to the presence of disease flares after discontinuation revealed no significant differences. All four patients experienced increased pleural effusions within 1 week of lenvatinib discontinuation. Progression-free survival ( Conclusions: The discontinuation of lenvatinib in patients with thymic carcinoma caused disease flare in 8% of cases, with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.